A Phase I, Open-Label, study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants

Trial Identifier: D6572C00002
Sponsor: AstraZeneca
NCTID:: NCT03276052
Start Date: October 2021
Primary Completion Date: November 2021
Study Completion Date: November 2021
Condition: Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Chinese Translation

Trial Locations

Country Location
CN Chengdu, CN, 610000